warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
LCI-HEM-AML-SCD-001: Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Brief Description  
Primary objective: To compare two-year relapse-free survival (RFS) of patients with acute myeloid leukemia (AML) with detectable leukemia stem cells (LSCs) in their bone marrow at end of treatment (eLSC+) to the two-year RFS of patients without detectable LSCs (eLSC-). Secondary objectives: a. Compare the one-year RFS of AML patients with detectable LSCs in their bone marrow at eLSC to the one-year RFS of AML patients without detectable LSCs at eLSC. b. Compare the two-year RFS of favor
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Leukemia, other
Status  
OPEN
Start Date  
09/19/2016
IRB Number  
00011138
Principal Investigator  
Grunwald, Michael Richard
Contact Name  
Asheton Asforis

For More Information, Contact  Asheton  , Asforis
Phone:  980-442-2345 Fax:    
Email:  Asheton.Asforis@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close